The clinical effects of inclisiran, a first-in-class LDL-C lowering siRNA therapy, on the LDL-C levels in Chinese patients with hypercholesterolemia

Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death and disability worldwide and is expected to remain so beyond 2040 1. In China, cardiovascular disease (CVD) is the leading cause of death and is responsible for 40% of deaths in the Chinese population 2. One unique feature of the CVD in Chinese patient population is that the burden of ASCVD has rapidly and substantially increased, therefore, effective treatment of ASCVD should be considered a top priority for prevention of CVD in China 2.
Source: Journal of Clinical Lipidology - Category: Lipidology Authors: Source Type: research